$2.81+0.13 (+4.85%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD
Liminatus Pharma (LIMN) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireSep 29, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
FULLERTON, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq's minimum bid price rule.…

● GlobeNewsWireAug 24, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biotechnology company developing innovative cancer therapies, today announced that it has engag…
Press releases · the company's own words
GlobeNewsWire · Sep 29, 2026
GlobeNewsWire · Aug 24, 2026
Kept in their own lane. A press release is the company talking, not reporting.
Tied to events
No upcoming events in the feeds.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

